Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Ascendi Pharma, commonly known as Ascendi, is a leading speciality pharmaceutical company headquartered in Denmark (DK). Established in 2011, it has rapidly grown into a significant force in pharmaceutical preparation manufacturing, focused on developing and commercialising a diverse portfolio of niche and orphan medicinal products.
Ascendi addresses critical unmet patient needs across therapeutic areas such as Oncology, Haematology, Urology, and Rare Diseases. Leveraging robust regulatory and commercial capabilities, the company delivers innovative pharmaceutical solutions to global markets. Ascendi achieves this through a direct sales presence in key European regions and strategic partnerships worldwide, ensuring broad patient access.
-13 vs industry average
Ascendi’s score of 29 is lower than 41% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Ascendi, a pharmaceutical preparation manufacturer based in DK, reported approximately 721,000 kg CO2e in market-based Scope 1 and 2 emissions for 2025. This figure represents an increase from approximately 609,000 kg CO2e in market-based Scope 1 and 2 emissions reported for 2024. For 2025, their Scope 1 emissions were 69,000 kg CO2e and market-based Scope 2 emissions were 652,000 kg CO2e. In 2024, Scope 1 emissions were 62,000 kg CO2e and market-based Scope 2 emissions were 547,000 kg CO2e.
Ascendi has a near-term Science Based Target initiative (SBTi) commitment to reduce absolute Scope 1 and 2 greenhouse gas emissions by 46.2% by 2031, from a 2025 base year. This target is classified as consistent with reductions required to keep warming to 1.5°C. As a small and medium-sized enterprise (SME), Ascendi also commits to measure and reduce its Scope 3 emissions. This emissions data and SBTi target originate directly from Ascendis Pharma A/S.
2031
46.2% reduction in Scope 1
ASCENDIS commits to reduce absolute scope 1 and scope 2 GHG emissions 46.2% by 2031 from a 2025 base year
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Ascendi’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more